Hypermethylation of the first exon of SLFN12 suggests repression of this gene in samples from MS patients, which is corroborated by decreased expression in whole blood of MS patients compared to controls (Table 4) in an independent cohort. This evidence concerns the gene SLFN12 and myeloid sarcoma.